Sanofi (SNY) Stock News

Sanofi had guided for 2026 sales to grow by around 10% at constant currency, with business EPS growth faster than 10% at constant currency.

Sanofi guides 2026 sales to low-teens constant-currency growth.

Sanofi 3Q adjusted EPS EUR3.55, revenue beats estimates.

Sanofi reported third-quarter sales of EUR14.44 billion. No further detail was provided in the initial release.

Sanofi 3Q vaccine sales fall 6.6% to EUR3.185B.

Analysts expected Sanofi 3Q business EPS of EUR2.81.

Analysts expect Sanofi to report third-quarter business operating profit of EUR4.32 billion. Actual results are due later today.

Sanofi 3Q launch sales rise 31% to EUR1.39B.

Sanofi lifted its 2026 guidance. No specific figures were given in the initial report.

Sanofi 3Q Dupixent sales rise 35% to EUR5.69B.

Sanofi reported Q3 net sales of EUR14.4 billion, up 14.3% at constant exchange rates, and business EPS of EUR3.55, up 19.6% at CER. Dupixent sales rose 34.8% to EUR5.7 billion. The company upgraded its full-year guidance to low-teens sales growth and mid-teens business EPS growth at CER.

Sanofi posted third-quarter revenue of EUR 14.4 billion, exceeding the FactSet consensus estimate of EUR 13.6 billion. Free cash flow for the quarter came in at EUR 3.27 billion.

Sanofi 3Q Operating Profit EUR4.35B.

Sanofi 3Q sales beat analyst consensus.

Sanofi reports Q3 Friday. Consensus: €13.25B sales, €2.81 business EPS. Focus on dealmaking after Regeneron expansion, new CEO and R&D head, guidance outlook, and vaccine weakness.

Sanofi: Nuvaxovid Covid-19 vaccine available across all Canadian provinces and Yukon.

Sanofi announced the availability of its Nuvaxovid Covid-19 vaccine for Canadians for the 2026-2027 respiratory season, expanding vaccine choice.

The venture arm of Sanofi is part of Rezera's investor group.

Sanofi broke ground on a new insulin manufacturing facility at its Frankfurt BioCampus. The 36,000-square-meter plant will use advanced digital and AI technologies. Full production of insulin active pharmaceutical ingredient is planned for 2032. The project received European Commission-approved public support in September 2026.

Wolfe Research has initiated coverage on Sanofi.

Berenberg analysts say Sanofi's expanded Regeneron collaboration frees it to deploy €30B-€40B on M&A to refill its late-stage pipeline. Next key data: frexalimab in MS and brivekimig in HS, both due H2 2027. Shares up 1%.

RBC Capital Markets initiated coverage of Sanofi with a Sector Perform rating and an €80 price target.